The Joint Corp (JYNT)vsNovartis AG ADR (NVS)
JYNT
The Joint Corp
$8.86
-2.21%
HEALTHCARE · Cap: $130.05M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 102964% more annual revenue ($56.58B vs $54.90M). NVS leads profitability with a 23.9% profit margin vs 5.3%. NVS appears more attractively valued with a PEG of 2.48. NVS earns a higher WallStSmart Score of 51/100 (C-).
JYNT
Hold39
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.9%
Fair Value
$16.44
Current Price
$8.86
$7.58 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 6277.0% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 8.4x book value
3.1% revenue growth
Smaller company, higher risk/reward
5.3% margin — thin
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : JYNT
The strongest argument for JYNT centers on EPS Growth, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : JYNT
The primary concerns for JYNT are Price/Book, Revenue Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
JYNT profiles as a value stock while NVS is a declining play — different risk/reward profiles.
JYNT carries more volatility with a beta of 1.23 — expect wider price swings.
JYNT is growing revenue faster at 3.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 39/100), backed by strong 23.9% margins. JYNT offers better value entry with a 47.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Joint Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?